

Fig. S7

Α



В


EA.hy926 endothelial cell line control



anti-Fn antibody

Merged: phase contrast, anti-FN antibody,Hoechst 33342

CCD-32Sk fibroblast cell line, control







Merged: phase contrast, anti-FN antibody,Hoechst 33342



С



DOC insoluble



EA.hy926 + Fn siRNA





Merged: phase contrast, anti-

FN antibody, Hoechst 33342

anti-Fn antibody

CCD-32Sk + Fn siRNA





anti-Fn antibody

Merged: phase contrast, anti-FN antibody, Hoechst 33342




Fig. S7: Augmenting effect on bacterial uptake efficacy by Fn silencing in fibroblast cell line. (A) After three days of growth, the DOC insoluble and the DOC soluble protein fraction of EA.hy926 endothelial cell line and CCD-32Sk fibroblast cell line were harvested and analyzed by Western blotting (see also Fig. S2). Data are means \pm SD of Western blot quantification of three independent experiments. ** *p*≤0.01, unpaired t-test. (B) Representative images of Fn expression on EA.hy926 endothelial cells and CCD-32Sk fibroblasts without and with Fn silencing by Fn siRNA detected by immunofluorescence microscopy using an antibody against Fn (red) and Hoechst 33342 for nucleic acid staining (blue). (C) Lysostaphin protection assay was performed to quantify intracellular bacteria one hour post infection of either EA.hy926 or CCD-32Sk cells with *S. carnosus* TM300(pFNBA4) without and with Fn silencing by Fn siRNA. Data are means \pm SD of three independent experiments. * *p*<0.05, unpaired t-test.